Skip to main content

Table 2 WOMAC score before administration of treatments and 3, 6 and 12 months afterwards

From: Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II)

WOMAC Time Control BM-MSCs
Low-dose High-dose
Pain Baseline 5.5 (5, 6) 7.5 (5, 9) 4.5 (4, 5)
3 months 3 (1, 3)* 3.5 (3, 7) 3 (2, 5)
6 months 2.5 (1, 5)* 3.5 (3, 7) 3.5 (2, 5)
12 months 2 (1, 6) 3.5 (3, 5) 2.5 (2, 4)*
Stiffness Baseline 2 (1, 3) 4 (2, 5) 2.5 (2, 4)
3 months 2 (1, 2) 2 (0, 4) 2 (1, 2)
6 months 0.5 (0, 2) 1.5 (1, 3)* 2 (1, 3)
12 months 2 (1, 2) 2 (1, 2)* 2 (1, 2)*
Function Baseline 21 (13, 24) 26.5 (23, 32) 19 (12, 25)
3 months 9 (7, 11)* 17.5 (8, 26) 10 (7, 18)
6 months 7.5 (2, 13)* 18 (10, 23) 14.5 (8, 17)
12 months 9.5 (5, 23) 17 (10, 20) 11 (9, 14)*
Overall Baseline 29 (19, 38) 37 (32, 42) 28 (16, 34)
3 months 12 (11, 14)* 25.5 (11, 37) 13 (11, 26)*
6 months 10 (4, 20)* 24 (13, 31) 20 (13, 23)
12 months 13.5 (8, 33) 21.5 (15, 26) 16.5 (12, 19)**
  1. The values of each one of the three WOMAC subscales as well as the overall WOMAC score at baseline and 3, 6 and 12 months afterwards are presented. Data are the median (IQR) of each group. Function means physical function. *p < 0.05, **p < 0.01 with respect to the baseline value of the same group